Synthetic ghrelin - BioPharma Forest/KineMed

Drug Profile

Synthetic ghrelin - BioPharma Forest/KineMed

Latest Information Update: 21 Nov 2015

Price : $50

At a glance

  • Originator Biopharma Forest
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Muscular atrophy

Most Recent Events

  • 20 Nov 2015 Phase-II clinical trials in Muscular atrophy in Japan (SC)
  • 22 Sep 2015 Phase-I clinical trials in Muscular atrophy in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top